Credit Suisse’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Credit Suisse’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	-$3	–	3811
2022 Q4	–	Sell	-3,776	Closed	-$66.6K	–	3877
2022 Q3	$80K	Buy	3,776 +34	+0.9%	+$917	﹤0.01%	3479
2022 Q2	$90K	Buy	3,742 +47	+1%	+$1.6K	﹤0.01%	3556
2022 Q1	$184K	Buy	3,695 +241	+7%	+$11.9K	﹤0.01%	3390
2021 Q4	$241K	Buy	3,454 +99	+3%	+$8.34K	﹤0.01%	4209
2021 Q3	$313K	Buy	3,355 +357	+12%	+$33.9K	﹤0.01%	4072
2021 Q2	$301K	Sell	2,998 -2,550	-46%	-$249K	﹤0.01%	4109
2021 Q1	$518K	Sell	5,548 -14,631	-73%	-$1.48M	﹤0.01%	3748
2020 Q4	$1.67M	Sell	20,179 -3,556	-15%	-$303K	﹤0.01%	2960
2020 Q3	$2.04M	Buy	23,735 +23,095	+3,609%	+$2.69M	﹤0.01%	2415
2020 Q2	$60K	Buy	+640	New	+$35.3K	﹤0.01%	3866
2020 Q1	–	Sell	-2,453	Closed	-$102K	–	4302
2019 Q4	$102K	Buy	2,453 +1,780	+264%	+$39K	﹤0.01%	4068
2019 Q3	$9K	Buy	673 +241	+56%	+$5.05K	﹤0.01%	4095
2019 Q2	$15K	Sell	432 -1,272	-75%	-$69K	﹤0.01%	4054
2019 Q1	$96K	Buy	1,704 +1,371	+412%	+$74.2K	﹤0.01%	3847
2018 Q4	$16K	Buy	+333	New	+$18.3K	﹤0.01%	3838
2018 Q2	–	Sell	-534	Closed	-$56K	–	4181
2018 Q1	$56K	Buy	+534	New	+$63.7K	﹤0.01%	3871
2017 Q4	–	Sell	-490	Closed	-$57K	–	4245
2017 Q3	$57K	Buy	+490	New	+$58.9K	﹤0.01%	4138
2017 Q2	–	Sell	-375	Closed	-$62K	–	3991
2017 Q1	$62K	Buy	+375	New	+$50.8K	﹤0.01%	3729

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Credit Suisse's VBIV Position: Q1 2023 in Review

Credit Suisse held its VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3811.

Credit Suisse first reported a position in VBIV in Q1 2017 and has held it in 18 quarters since. The position peaked at $2.04M in Q3 2020. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

Credit Suisse held 0 shares of VBI Vaccines, Inc. New Common Stock (Canada) worth $0 as of Q1 2023.
Credit Suisse left its VBI Vaccines, Inc. New Common Stock (Canada) share count unchanged in Q1 2023.
VBI Vaccines, Inc. New Common Stock (Canada) made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3811 holding.
Credit Suisse first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2017 and has held it in 18 quarters since.
Credit Suisse's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2.04M in Q3 2020.
95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.